C08B37/0015

POLYROTAXANE, POLYMER COMPOSITION, CROSSLINKED POLYMER COMPOSITION, AND PRODUCTION METHOD THEREFOR

The present invention provides a crosslinked polymer composition exhibiting significantly improved elongation at break over conventional ones, and a polymer composition and a polyrotaxane, each of which can be used as a raw material of the crosslinked polymer composition.

The polyrotaxane contains a linear molecule, a cyclic molecule, and a blocking group, wherein the cyclic molecule has a hydrosilyl group. The polymer composition contains the polyrotaxane and a polymer, wherein the polymer has a double bond on at least either a main chain or a side chain. The crosslinked polymer composition is produced by crosslinking of the polymer composition through chemical reaction between the hydrosilyl group of the cyclic molecule and the double bond of the polymer.

EXCIPIENTS PROVIDING STABILIZATION AND ENHANCED WATER SOLUBILIZATION AND THEIR USES

Four major polymeric architectures, namely: (a) linear, (b) branched, (c) hyperbranched/dendritic and (d) cross-linked polymers, when formed by reaction of multifunctional alcohols, such as sugar-based alpha-, beta- or gamma-cyclodextrins, with multi-carboxylic acids form unique polyester copolymers. These copolymers have been demonstrated to substantially enhance the water-solubility and bioavailability of water insoluble compounds for a wide variety of uses.

POLYROTAXANE AND PRODUCTION METHOD THEREFOR, AND CROSSLINKED POLYROTAXANE

A polyrotaxane of high heat resistance contains a linear molecule, a cyclic molecule enclosing the linear molecule such that the cyclic molecule is skewered with the linear molecule, and 5 blocking groups disposed at both ends of the linear molecule. The cyclic molecule contains an aromatic ring having, on a side chain, a phenolic hydroxyl group. The polyrotaxane can be produced by dissolving, in a methanol-containing solvent, a linear molecule and a cyclic 10 molecule containing an aromatic ring having, on a side chain, a phenolic hydroxyl group, to yield a pseudo polyrotaxane in which the cyclic molecule encloses the linear molecule such that the cyclic molecule is skewered with the linear molecule; and dissolving the pseudo polyrotaxane and a blocking group 15 material in a solvent, to dispose blocking groups at both ends of the linear molecule.

COMPOSITIONS AND METHODS OF PROMOTING CELLULAR HYDRATION
20220323431 · 2022-10-13 · ·

A beverage composition promotes cellular hydration when ingested by a multicellular organism, and includes a carbohydrate clathrate component that includes cyclodextrin, in a concentration of 0.01-5% w/w. A complex-forming compound is also included in a concentration that is less than the clathrate component, and there is an aqueous liquid component, such as still and carbonated aqueous liquids. An inclusion complex is formed with at least some of the clathrate component and at least some of the complex-forming compound and the composition promotes cellular hydration of the multicellular organism when the multicellular organism ingests it. There is also a beverage composition that increases lifespan in the multicellular organism, and methods of promoting cellular hydration and increasing lifespan of the multicellular organism according to a mechanism of action.

COMPOSITIONS AND METHODS FOR DIFFERENTIAL RELEASE OF 1-METHYLCYCLOPROPENE

A clathrate of 1-methylcyclopropene with α-cyclodextrin, obtained as a solid particulate product, is modified by comminuting, classifying, or both to obtain a modified particulate. When subjected to identical atmospheric disgorgement conditions of humidity and temperature, identical masses of the modified and unmodified particulates exhibit different rates of 1-methylcyclopropene disgorgement. Specifically, we have found that a smaller mean particle size is inversely related to a greater rate of 1-methylcyclopropene release.

DRUG DELIVERY CARRIER INCLUDING PLGA AND BETA-CYCLODEXTRIN CONTAINING DRUG

Provided is a drug delivery carrier including PLGA and β-cyclodextrin containing a drug. According to the drug delivery carrier, the time during which a drug stays in the living body may be prolonged, and due to the biodegradation thereof, few side effects occur.

Pharmaceutical compositions comprising meloxicam
11602563 · 2023-03-14 · ·

Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.

Compositions and methods for improved honey bee health

Compositions comprising a mixture of at least one cyclodextrin, a carrier, and optionally one or more vitamins and/or nutrients to improve at least one health factor of a beehive is disclosed. Methods of improving beehive health and apparatuses including such compositions are also disclosed.

Water dissolvable macrocyclic lactone cyclodextrin complexes
11638714 · 2023-05-02 · ·

Injectable Ivermectin solution is safely administrable to humans and animals used the disclosed technology. A macrocyclic lactone cyclodextrin complex which is completely dissolvable or dissolved in water in a ratio of at least 10-20 milligrams of the macrocyclic lactone complex per 5 milliliters of water. The macrocyclic lactone cyclodextrin complex is non-toxic, without using organic solvents, and in embodiments, formed by adding a surfactant to the macrocyclic lactone complex to water. The macrocyclic lactone cyclodextrin complex is Ivermectin or an Ivermectin derivative in some embodiments. The cyclodextrin complex is 2-hydroxypropyl-beta-cyclodextrin in some embodiments of the disclosed technology. The surfactant can be polysorbate 80 and is in a ratio of 0.01% to 25%, by weight, to said water. The water soluble complexes can be added to the water. The water-soluble complexes can have at least one of an anti-parasitic, anti-viral and anti-cancer complex.